Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Ceritinib is a novel triple negative breast cancer therapeutic agent

Fig. 2

Delineation of molecular mechanisms of ceritinib effects on LAR killing. (A) Ceritinib treatment dramatically inhibited RTK-ACK1-AR signaling in time course in MDA-MB 453 cells and (B) MFM223 cells. Ceritinib treatment also dramatically suppressed AKT-mTOR signaling in MDA-MB 453 cells (C) and MFM223 cells (D) in time course. Cell skeleton protein vinculin was used as a protein loading control

Back to article page